Pharma R&D
Iteru’s Provides a Powerful Platform for Pharma R&D
The availability of a large pool of integrated cleansed non-multimodal and multimodal data and powerful AI analysis tools at the fingertips of a researcher offer the ability to gather information and perform comprehensive analysis of biomedical data. Iteru’s platform can be used to identify new targets. It can be used for drug repurposing. Iteru’s preprocessing renders data in a form amenable to integrating new algorithms to increase the functionality of R&D. The platform can be used to address different aspects of pharma R&D by expanding its repertoire of AI algorithms. Aspects of R&D that can be covered include: patient stratification, optimize clinical trial designs, predict outcomes, and identify potential issues early in the process.
Simulation of Drug Repurposing
(Viagra Repurposed from a Candidate Drug)
Viagra was discovered by accident when investigating the candidate drug PDE5 inhibitors (UK-92.480) for pulmonary hypertension. The following case study was proposed to Iteru: assuming Iteru’s software was existing in early 1989, when UK-92.480 was suggested as a candidate drug would Iteru had been able to discover Viagra based on the drug’s mechanism of action.
Iteru uncovered many research papers dated 1984 – 1989 explicitly indicating that PDE5 inhibitors causes penile erection. The papers were published 5 years before research started om UK-92.480 and 14 years before Viagra was approved.
VIOXX Toxicity
VIOXX is a drug developed by a big pharmaceutical company. its toxicity caused many fatalities in the nineties. The following case study was proposed by a pharma executive: If Iteru’s software was existing in 1998, using the mechanism of action for VIOXX, would Iteru had been able to uncover VIOXX toxicity. The mechanism of action reduces the production of prostaglandins, which causes pain and inflammation. The company that developed VIOXX had to pay the costly price of withdrawing the drug, including $4.85B to end lawsuits.
Iteru uncovered many research papers, dated 1985-1990, warning that changes in the level of prostaglandins is involved in various diseases including ischemic heart disease and thrombotic disorder. The publications existed 11 years before the start of VIOXX development.